Cancer Research and Treatment

Original Article

Gastrointestinal cancer

Effector Function Characteristics of Exhausted CD8+ T-Cell in Microsatellite Stable and Unstable Gastric Cancer: Dong-Seok Han, Yoonjin Kwak, Seungho Lee, Soo Kyung Nam, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Nak-Jung Kwon, Hye Seung Lee, Han-Kwang Yang; Cancer Res Treat. 2024;56(4):1146-1163. Published online April 12, 2024; DOI: https://doi.org/10.4143/crt.2024.317

Purpose
Gastric cancer exhibits molecular heterogeneity, with the microsatellite instability–high (MSI-H) subtype drawing attention for its distinct features. Despite a higher survival rate, MSI-H gastric cancer lack significant benefits from conventional chemotherapy. The immune checkpoint inhibitors, presents a potential avenue, but a deeper understanding of the tumor immune microenvironment of MSI-H gastric cancer is essential.
Materials and Methods
We explored the molecular characteristics of CD8+ T-cell subtypes in three MSI-H and three microsatellite stable (MSS) gastric cancer samples using single-cell RNA sequencing and spatial transcriptome analysis.
Results
In MSI-H gastric cancer, significantly higher proportions of effector memory T cell (Tem), exhausted T cell (Tex), proliferative exhausted T cell (pTex), and proliferative T cell were observed, while MSS gastric cancer exhibited significantly higher proportions of mucosal-associated invariant T cell and natural killer T cell. In MSI-H gastric cancer, Tex and pTex exhibited a significant upregulation of the exhaustion marker LAG3, as well as elevated expression of effector function markers such as IFNG, GZMB, GZMH, and GZMK, compared to those in MSS gastric cancer. The interferon γ (IFN-γ) signaling pathway of Tex and pTex was retained compared to those of MSS gastric cancer. The spatial transcriptome analysis demonstrates the IFN-γ signaling pathway between neighboring Tex and malignant cell, showcasing a significantly elevated interaction in MSI-H gastric cancer.
Conclusion
Our study reveals novel finding indicating that IFN-γ signaling pathway is retained in Tex and pTex of MSI-H gastric cancer, offering a comprehensive perspective for future investigations into immunotherapy for gastric cancer.

Citations

Citations to this article as recorded by

Simvastatin induces ferroptosis and activates anti-tumor immunity to sensitize anti-PD-1 immunotherapy in microsatellite stable gastric cancer
Yumei Ning, Shilin Fang, Runan Zhang, Jun Fang, Kun Lin, Yang Ding, Haihang Nie, Jingkai Zhou, Qiu Zhao, Hengning Ke, Haizhou Wang, Fan Wang
International Immunopharmacology.2024; 142: 113244. CrossRef

2,611 View
168 Download
1 Crossref

Review Article

Applicability of Spatial Technology in Cancer Research: Sangjeong Ahn, Hye Seung Lee; Cancer Res Treat. 2024;56(2):343-356. Published online January 30, 2024; DOI: https://doi.org/10.4143/crt.2023.1302

Abstract PDF PubReader ePub

This review explores spatial mapping technologies in cancer research, highlighting their crucial role in understanding the complexities of the tumor microenvironment (TME). The TME, which is an intricate ecosystem of diverse cell types, has a significant impact on tumor dynamics and treatment outcomes. This review closely examines cutting-edge spatial mapping technologies, categorizing them into capture-, imaging-, and antibody-based approaches. Each technology was scrutinized for its advantages and disadvantages, factoring in aspects such as spatial profiling area, multiplexing capabilities, and resolution. Additionally, we draw attention to the nuanced choices researchers face, with capture-based methods lending themselves to hypothesis generation, and imaging/antibody-based methods that fit neatly into hypothesis testing. Looking ahead, we anticipate a scenario in which multi-omics data are seamlessly integrated, artificial intelligence enhances data analysis, and spatiotemporal profiling opens up new dimensions.

Citations

Citations to this article as recorded by

Navigating the landscape of plant proteomics
Tian Sang, Zhen Zhang, Guting Liu, Pengcheng Wang
Journal of Integrative Plant Biology.2025;[Epub] CrossRef
Distinctive Phenotypic and Microenvironmental Characteristics of Neuroendocrine Carcinoma and Adenocarcinoma Components in Gastric Mixed Adenoneuroendocrine Carcinoma
Yoonjin Kwak, Soo Kyung Nam, Yujun Park, Yun-Suhk Suh, Sang-Hoon Ahn, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Hyung-Ho Kim, Han-Kwang Yang, Hye Seung Lee
Modern Pathology.2024; 37(10): 100568. CrossRef
Effector Function Characteristics of Exhausted CD8+ T-Cell in Microsatellite Stable and Unstable Gastric Cancer
Dong-Seok Han, Yoonjin Kwak, Seungho Lee, Soo Kyung Nam, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Nak-Jung Kwon, Hye Seung Lee, Han-Kwang Yang
Cancer Research and Treatment.2024; 56(4): 1146. CrossRef
Prognostic significance of CD8 and TCF1 double positive T cell subset in microsatellite unstable gastric cancer
Juhyeong Park, Soo Kyung Nam, Yoonjin Kwak, Hyeon Jeong Oh, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Han-Kwang Yang, Hye Seung Lee
Scientific Reports.2024;[Epub] CrossRef

4,841 View
250 Download
4 Web of Science
4 Crossref

Special Article

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP: Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim; Cancer Res Treat. 2024;56(3):721-742. Published online November 29, 2023; DOI: https://doi.org/10.4143/crt.2023.1043

Abstract PDF PubReader ePub: In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

5,638 View
317 Download

Original Articles

Gastrointestinal cancer

Genomic and Transcriptomic Characterization of Gastric Cancer with Bone Metastasis: Sujin Oh, Soo Kyung Nam, Keun-Wook Lee, Hye Seung Lee, Yujun Park, Yoonjin Kwak, Kyu Sang Lee, Ji-Won Kim, Jin Won Kim, Minsu Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim; Cancer Res Treat. 2024;56(1):219-237. Published online August 11, 2023; DOI: https://doi.org/10.4143/crt.2023.340

Abstract PDF Supplementary Material PubReader ePub

Purpose
Bone metastasis (BM) adversely affects the prognosis of gastric cancer (GC). We investigated molecular features and immune microenvironment that characterize GC with BM compared to GC without BM.
Materials and Methods
Targeted DNA and whole transcriptome sequencing were performed using formalin-fixed paraffin-embedded primary tumor tissues (gastrectomy specimens) of 50 GC cases with distant metastases (14 with BM and 36 without BM). In addition, immunohistochemistry (IHC) for mucin-12 and multiplex IHC for immune cell markers were performed.
Results
Most GC cases with BM had a histologic type of poorly cohesive carcinoma and showed worse overall survival (OS) than GC without BM (p < 0.05). GC with BM tended to have higher mutation rates in TP53, KDR, APC, KDM5A, and RHOA than GC without BM. Chief cell-enriched genes (PGA3, PGC, and LIPF), MUC12, MFSD4A, TSPAN7, and TRIM50 were upregulated in GC with BM compared to GC without BM, which was correlated with poor OS (p < 0.05). However, the expression of SERPINA6, SLC30A2, PMAIP1, and ITIH2 were downregulated in GC with BM. GC with BM was associated with PIK3/AKT/mTOR pathway activation, whereas GC without BM showed the opposite effect. The densities of helper, cytotoxic, and regulatory T cells did not differ between the two groups, whereas the densities of macrophages were lower in GC with BM (p < 0.05).
Conclusion
GC with BM had different gene mutation and expression profiles than GC without BM, and had more genetic alterations associated with a poor prognosis.

Citations

Citations to this article as recorded by

Targeted Sequencing in Gastric Cancer: Association with Tumor Molecular Characteristics and FLOT Therapy Effectiveness
Liudmila V. Spirina, Alexandra V. Avgustinovich, Olga V. Bakina, Sergey G. Afanas’ev, Maxim Yu. Volkov, Sergey V. Vtorushin, Irina V. Kovaleva, Tatyana S. Klyushina, Igor O. Munkuev
Current Issues in Molecular Biology.2024; 46(2): 1281. CrossRef
SLC30A2-Mediated Zinc Metabolism Modulates Gastric Cancer Progression via the Wnt/β-Catenin Signaling Pathway
Fan Li, Xiaohong Zhang, Li Feng, Xingxing Zhang
Frontiers in Bioscience-Landmark.2024;[Epub] CrossRef
Primary mucinous cystadenocarcinoma of the breast: A case report and literature review
Xi Cao, Yongchao Luo, Songjie Shen, Xinyu Ren
Oncology Letters.2024;[Epub] CrossRef

4,317 View
228 Download
3 Web of Science
3 Crossref

Development and Validation of Models to Predict Lymph Node Metastasis in Early Gastric Cancer Using Logistic Regression and Gradient Boosting Machine Methods: Hae Dong Lee, Kyung Han Nam, Cheol Min Shin, Hye Seung Lee, Young Hoon Chang, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sang-Hoon Ahn, Hyung-Ho Kim; Cancer Res Treat. 2023;55(4):1240-1249. Published online March 21, 2023; DOI: https://doi.org/10.4143/crt.2022.1330

Abstract PDF Supplementary Material PubReader ePub

Purpose
To identify important features of lymph node metastasis (LNM) and develop a prediction model for early gastric cancer (EGC) using a gradient boosting machine (GBM) method.
Materials and Methods
The clinicopathologic data of 2556 patients with EGC who underwent gastrectomy were used as training set and the internal validation set (set 1) at a ratio of 8:2. Additionally, 548 patients with EGC who underwent endoscopic submucosal dissection (ESD) as the initial treatment were included in the external validation set (set 2). The GBM model was constructed, and its performance was compared with that of the Japanese guidelines.
Results
LNM was identified in 12.6% (321/2556) of the gastrectomy group (training set & set 1) and 4.3% (24/548) of the ESD group (set 2). In the GBM analysis, the top five features that most affected LNM were lymphovascular invasion, depth, differentiation, size, and location. The accuracy, sensitivity, specificity, and the area under the receiver operating characteristics of set 1 were 0.566, 0.922, 0.516, and 0.867, while those of set 2 were 0.810, 0.958, 0.803, and 0.944, respectively. When the sensitivity of GBM was adjusted to that of Japanese guidelines (beyond the expanded criteria in set 1 [0.922] and eCuraC-2 in set 2 [0.958]), the specificities of GBM in sets 1 and 2 were 0.516 (95% confidence interval, 0.502-0.523) and 0.803 (0.795-0.805), while those of the Japanese guidelines were 0.502 (0.488-0.509) and 0.788 (0.780-0.790), respectively.
Conclusion
The GBM model showed good performance comparable with the eCura system in predicting LNM risk in EGCs.

Citations

Citations to this article as recorded by

Establishment of a machine learning model for predicting splenic hilar lymph node metastasis
Kenichi Ishizu, Satoshi Takahashi, Nobuji Kouno, Ken Takasawa, Katsuji Takeda, Kota Matsui, Masashi Nishino, Tsutomu Hayashi, Yukinori Yamagata, Shigeyuki Matsui, Takaki Yoshikawa, Ryuji Hamamoto
npj Digital Medicine.2025;[Epub] CrossRef
Intratumoural and peritumoural CT-based radiomics for diagnosing lepidic-predominant adenocarcinoma in patients with pure ground-glass nodules: a machine learning approach
Y. Zou, Q. Mao, Z. Zhao, X. Zhou, Y. Pan, Z. Zuo, W. Zhang
Clinical Radiology.2024; 79(2): e211. CrossRef
eCura and W-eCura: different scores, different populations, same goal
Rui Morais, Diogo Libanio, João Santos-Antunes
Gut.2024; 73(11): e29. CrossRef
A machine learning model for predicting the lymph node metastasis of early gastric cancer not meeting the endoscopic curability criteria
Minoru Kato, Yoshito Hayashi, Ryotaro Uema, Takashi Kanesaka, Shinjiro Yamaguchi, Akira Maekawa, Takuya Yamada, Masashi Yamamoto, Shinji Kitamura, Takuya Inoue, Shunsuke Yamamoto, Takashi Kizu, Risato Takeda, Hideharu Ogiyama, Katsumi Yamamoto, Kenji Aoi,
Gastric Cancer.2024; 27(5): 1069. CrossRef
The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide
Amin Zadeh Shirazi, Morteza Tofighi, Alireza Gharavi, Guillermo A. Gomez
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Computed Tomography-Based Radiomics Analysis of Different Machine Learning Approaches for Differentiating Pulmonary Sarcomatoid Carcinoma and Pulmonary Inflammatory Pseudotumor
An-Lin Zhang, Yan-Mei Fu, Zhi-Yang He
Iranian Journal of Radiology.2024;[Epub] CrossRef
Screening of gastric cancer diagnostic biomarkers in the homologous recombination signaling pathway and assessment of their clinical and radiomic correlations
Ahao Wu, Tengcheng Hu, Chao Lai, Qingwen Zeng, Lianghua Luo, Xufeng Shu, Pan Huang, Zhonghao Wang, Zongfeng Feng, Yanyan Zhu, Yi Cao, Zhengrong Li
Cancer Medicine.2024;[Epub] CrossRef

5,336 View
220 Download
7 Web of Science
7 Crossref

Universal Screening for Lynch Syndrome Compared with Pedigree-Based Screening: 10-Year Experience in a Tertiary Hospital: Min Hyun Kim, Duck-Woo Kim, Hye Seung Lee, Su Kyung Bang, Soo Hyun Seo, Kyung Un Park, Heung-Kwon Oh, Sung-Bum Kang; Cancer Res Treat. 2023;55(1):179-188. Published online March 21, 2022; DOI: https://doi.org/10.4143/crt.2021.1512

Abstract PDF PubReader ePub

Purpose
Universal screening for Lynch syndrome (LS) refers to routine tumor testing for microsatellite instability (MSI) among all patients with colorectal cancer (CRC). Despite its widespread adoption, real-world data on the yield is lacking in Korean population. We studied the yield of adopting universal screening for LS in comparison with pedigree-based screening in a tertiary center.
Materials and Methods
CRC patients from 2007-2018 were reviewed. Family histories were obtained and were evaluated for hereditary nonpolyposis colorectal cancer (HNPCC) using Amsterdam II criteria. Tumor testing for MSI began in 2007 and genetic testing was offered using all available clinicopathologic data. Yield of genetic testing for LS was compared for each approach and step.
Results
Of the 5,520 patients, tumor testing was performed in 4,701 patients (85.2%) and family histories were obtained from 4,241 patients (76.8%). Hereditary CRC (LS or HNPCC) was present in 69 patients (1.3%). MSI-high was present in 6.9%, and 25 patients had confirmed LS. Genetic testing was performed in 41.2% (47/114) of MSI-high patients, out of which 40.4% (19/47) were diagnosed with LS. There were six additional LS patients found outside of tumor testing. For pedigree-based screening, Amsterdam II criteria diagnosed 55 patients with HNPCC. Fifteen of these patients underwent genetic testing, and 11 (73.3%) were diagnosed with LS. Two patients without prior family history were diagnosed with LS and relied solely on tumor testing results.
Conclusion
Despite widespread adoption of routine tumor testing for MSI, this is not a fail-safe approach to screen all LS patients. Obtaining a thorough family history in combination with universal screening provides a more comprehensive ‘universal’ screening method for LS.

Citations

Citations to this article as recorded by

Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
Hyo Seon Ryu, Hyun Jung Kim, Woong Bae Ji, Byung Chang Kim, Ji Hun Kim, Sung Kyung Moon, Sung Il Kang, Han Deok Kwak, Eun Sun Kim, Chang Hyun Kim, Tae Hyung Kim, Gyoung Tae Noh, Byung-Soo Park, Hyeung-Min Park, Jeong Mo Bae, Jung Hoon Bae, Ni Eun Seo, Cha
Annals of Coloproctology.2024; 40(2): 89. CrossRef
Hereditary Colorectal Cancer: From Diagnosis to Surgical Options
Rami James N. Aoun, Matthew F. Kalady
Clinics in Colon and Rectal Surgery.2024;[Epub] CrossRef
Universal screening of colorectal tumors for lynch syndrome: a survey of patient experiences and opinions
Alexander T. Petterson, Jennifer Garbarini, Maria J. Baker
Hereditary Cancer in Clinical Practice.2024;[Epub] CrossRef
Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Hyunho Han, Minyong Kang, Seok-Soo Byun, Seok Joong Yun
Journal of Urologic Oncology.2023; 21(2): 128. CrossRef
Diagnosis of patients with Lynch syndrome lacking the Amsterdam II or Bethesda criteria
Miguel Angel Trujillo-Rojas, María de la Luz Ayala-Madrigal, Melva Gutiérrez-Angulo, Anahí González-Mercado, José Miguel Moreno-Ortiz
Hereditary Cancer in Clinical Practice.2023;[Epub] CrossRef
Hereditary Colorectal Cancer: State of the Art in Lynch Syndrome
Antonio Nolano, Alessia Medugno, Silvia Trombetti, Raffaella Liccardo, Marina De Rosa, Paola Izzo, Francesca Duraturo
Cancers.2022; 15(1): 75. CrossRef

5,130 View
167 Download
6 Web of Science
6 Crossref

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs: Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee; Cancer Res Treat. 2020;52(3):661-670. Published online January 10, 2020; DOI: https://doi.org/10.4143/crt.2019.718

Abstract PDF Supplementary Material PubReader ePub

Purpose
We provide a comparison between 22C3 pharmDx and SP263 assay, for evaluating programmed death ligand 1 (PD-L1) expression in advanced gastric cancer (GC) patients.
Materials and Methods
The PD-L1 immunohistochemistry by 22C3 pharmDx and SP263 assays was performed in the center of the tumor (CT) and invasive margin (IM) in 379 GC tissues using tissue microarrays and interpreted as combined positive score (CPS) and tumor proportion score (TPS). Of the total samples, 55 samples were independently reviewed by five pathologists.
Results
The two assays showed a high correlation in both the CPS and TPS. At a CPS ≥ 1 cut-off, 219 (57.8%) and 231 (60.9%) GCs were positive for PD-L1 with the 22C3 and SP263 assays, and at ≥ 10 cut-off, 37 (9.8%) and 36 (9.5%) GCs were positive, respectively. The overall percent agreement (OPA) was greater than 90% with CPS ≥ 1 and ≥ 10 cut-offs, and TPS ≥ 1% and ≥ 10% cut-offs. There was higher OPA between the two assays with a CPS cut-off ≥ 10 (99.2%) than ≥ 1 (94.7%). The percent agreement between the CT and IM was higher with a CPS cut-off ≥ 10 (92.9%) than ≥ 1 (77.6%). Patient with positive expression at CPS ≥ 5 cut-off had a significantly better outcomes in both assays. Interobserver variability among five pathologists was higher than the assay variability.
Conclusion
Two assays for PD-L1 expression in GC showed high agreement. These results provide guidance for selecting eligible patients with GC for pembrolizumab treatment.

Citations

Citations to this article as recorded by

PD-L1 as a Biomarker in Gastric Cancer Immunotherapy
Yunjoo Cho, Soomin Ahn, Kyoung-Mee Kim
Journal of Gastric Cancer.2025; 25(1): 177. CrossRef
CT radiomics-based intratumoral and intertumoral heterogeneity indicators for prognosis prediction in gastric cancer patients receiving neoadjuvant chemotherapy
Jiazheng Li, Zhenhui Li, Yinkui Wang, Yuzhuo Li, Jing Zhang, Ziyu Li, Lei Tang
European Radiology.2025;[Epub] CrossRef
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma
Clinical and Translational Oncology.2025;[Epub] CrossRef
Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
Mojun Zhu, Harry H. Yoon
Journal of Clinical Oncology.2024; 42(4): 373. CrossRef
Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, C
Dordi Lea, Claudia Zaharia, Kjetil Søreide
Cancer Treatment and Research Communications.2024; 38: 100788. CrossRef
The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study
Jeffry Beta Tenggara, Andhika Rachman, Joedo Prihartono, Lisnawati Rachmadi, Sonar Soni Panigoro, Didik Setyo Heriyanto, Noorwati Sutandyo, Intan Russianna Nasution, Familia Bella Rahadiati, Ricci Steven, Rachelle Betsy, Samuel Juanputra, Aru Wisaksono Su
BMC Research Notes.2024;[Epub] CrossRef
Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?
Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed
Current Treatment Options in Oncology.2024; 25(4): 496. CrossRef
Evaluation of PD-L1 Expression in Colorectal Carcinomas by Comparing Scoring Methods and Their Significance in Relation to Clinicopathologic Parameters
Mirela Frančina, Mislav Mikuš, Marin Mamić, Tihomir Jovanović, Mario Ćorić, Božica Lovrić, Ivan Vukoja, Goran Zukanović, Kristijan Matković, Jasmina Rajc, Ferdinand Slišurić, Mateja Jurić-Marelja, Goran Augustin, Ilijan Tomaš
Diagnostics.2024; 14(10): 1007. CrossRef
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review
J. Bos, T.S. Groen-van Schooten, C.P. Brugman, F.S. Jamaludin, H.W.M. van Laarhoven, S. Derks
Cancer Treatment Reviews.2024; 127: 102737. CrossRef
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy
Hyung-Don Kim, Jinho Shin, In Hye Song, Jaewon Hyung, Hyungeun Lee, Min-Hee Ryu, Young Soo Park
Gastric Cancer.2024; 27(4): 819. CrossRef
Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination
Haruki Ogawa, Hiroyuki Abe, Koichi Yagi, Yasuyuki Seto, Tetsuo Ushiku
Gastric Cancer.2024; 27(4): 802. CrossRef
Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists
Soomin Ahn, Yoonjin Kwak, Gui Young Kwon, Kyoung-Mee Kim, Moonsik Kim, Hyunki Kim, Young Soo Park, Hyeon Jeong Oh, Kyoungyul Lee, Sung Hak Lee, Hye Seung Lee
Journal of Pathology and Translational Medicine.2024; 58(3): 103. CrossRef
PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays
Samuel J. Klempner, Eric S. Cowden, Samuel L. Cytryn, Matteo Fassan, Hisato Kawakami, Hideaki Shimada, Laura H. Tang, Daniel-Christoph Wagner, Yasushi Yatabe, Alexander Savchenko, Jennifer Salcius, Dorhyun Johng, Jing Chen, Giuliana Montenegro, Markus Moe
JCO Precision Oncology.2024;[Epub] CrossRef
PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV
Lucília Lovane, Satish Tulsidás, Carla Carrilho, Christina Karlsson
Scientific Reports.2024;[Epub] CrossRef
First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population
Feiyang Zhang, Guoming Chen, Yixin Yin, Xiaojiang Chen, Runcong Nie, Yingbo Chen
Frontiers in Pharmacology.2024;[Epub] CrossRef
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study
V. Massa, F. Signorini, F. Salani, M.E. Filice, G. Grelli, P. Lippolis, P. Faviana, V. Genovesi, S. Santi, C. Vivaldi, S. Cesario, A. Bertolucci, C. Cremolini, V. Nardini, G. Masi, C. Ugolini, L. Fornaro
ESMO Gastrointestinal Oncology.2024; 5: 100089. CrossRef
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
Jifang Gong, Ye Guo, Yanqiao Zhang, Yi Ba, Tong Chen, Wei Li, Caicun Zhou, Mengzhao Wang, Haiyan Yang, Yuhong Zhou, Qiqing Cai, Ziping Wang, Gang Huang, Wei Zhang, Rila Su, Zhongheng Cai, Zenglian Yue, Jinzhou Dou, Peiqi Li, Rachel Wu, Archie N. Tse, Lin
Targeted Oncology.2024; 19(5): 723. CrossRef
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
A.G. Leone, A.S. Mai, K.Y. Fong, D.W.T. Yap, K. Kato, E. Smyth, M. Moehler, J.T.C. Seong, R. Sundar, J.J. Zhao, F. Pietrantonio
ESMO Open.2024; 9(11): 103962. CrossRef
HIPEC for Metastatic Gastric Cancer: Moving the Needle Towards 3-Year Survival
Neal Bhutiani, Y. David Seo, Kristen A. Robinson, Michael G. White, Naruhiko Ikoma, Paul F. Mansfield, Jenny J. Li, Mariela Blum Murphy, Jaffer A. Ajani, Brian D. Badgwell
European Journal of Surgical Oncology.2024; : 108790. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer
Moonsik Kim, Ji Yun Jeong, An Na Seo
Diagnostics.2023; 13(17): 2782. CrossRef
Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images
Abhishek Vahadane, Shreya Sharma, Devraj Mandal, Madan Dabbeeru, Josephine Jakthong, Miguel Garcia-Guzman, Shantanu Majumdar, Chung-Wein Lee
Computers in Biology and Medicine.2023; 152: 106337. CrossRef
CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors
Jiazheng Li, Zifan Chen, Yang Chen, Jie Zhao, Meng He, Xiaoting Li, Li Zhang, Bin Dong, Xiaotian Zhang, Lei Tang, Lin Shen
Frontiers in Oncology.2023;[Epub] CrossRef
Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
Gengwei Huo, Wenjie Liu, Peng Chen
BMC Cancer.2023;[Epub] CrossRef
Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer
Joan Choo, Ley Fang Kua, Mu Yar Soe, Bernadette Reyna Asuncion, Benjamin Kye Jyn Tan, Chong Boon Teo, Ryan Yong Kiat Tay, Jimmy So, Asim Shabbir, Kim Guowei, Hon Lyn Tan, Gloria Chan, Haoran Ma, Gokula Krishnan Ramachandran, Jeffrey H. Y. Lum, Cheng Ean C
Gastric Cancer.2023; 26(3): 393. CrossRef
Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
Hyun Jung Kwon, Yujun Park, Soo Kyung Nam, Enoch Kang, Ka‐Kyung Kim, Inhae Jeong, Yoonjin Kwak, Jeesun Yoon, Tae‐Yong Kim, Keun‐Wook Lee, Do‐Youn Oh, Seock‐Ah Im, Seong‐Ho Kong, Do Joong Park, Hyuk‐Joon Lee, Hyung‐Ho Kim, Han‐Kwang Yang, Hye Seung Lee
Cancer Medicine.2023; 12(9): 10371. CrossRef
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Marie E. Robert, Josef Rüschoff, Bharat Jasani, Rondell P. Graham, Sunil S. Badve, Manuel Rodriguez-Justo, Liudmila L. Kodach, Amitabh Srivastava, Hanlin L. Wang, Laura H. Tang, Giancarlo Troncone, Federico Rojo, Benjamin J. Van Treeck, James Pratt, Iryna
Modern Pathology.2023; 36(5): 100154. CrossRef
Heterogeneous distribution pattern of CD3+ tumor-infiltrated lymphocytes (TILs) and high combined positive score (CPS) favored the prognosis of resected early stage small-cell lung cancer
Liang Zhu, Guoping Cheng, Meijuan Wu, Ming Chen, Ying Jin
Translational Oncology.2023; 34: 101697. CrossRef
The Role of Immunotherapy in Esophageal and Gastric Cancer
Hans Dedecker, Laure-Anne Teuwen, Timon Vandamme, Andreas Domen, Hans Prenen
Clinical Colorectal Cancer.2023; 22(2): 175. CrossRef
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer
Luca Licata, Marco Mariani, Federico Rossari, Giulia Viale, Giulia Notini, Matteo Maria Naldini, Carlo Bosi, Marta Piras, Matteo Dugo, Giampaolo Bianchini
The Breast.2023; 69: 330. CrossRef
PD‐L1andHLA‐class I expression status and their therapeutic implication in oesophageal small‐cell carcinoma
Satoshi Yamashita, Hiroyuki Abe, Hiroharu Yamashita, Koichi Yagi, Yasuyuki Seto, Tetsuo Ushiku
Histopathology.2023; 83(2): 264. CrossRef
Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer
Taned Chitapanarux, Pawut Gumrai, Sarawut Kongkarnka, Komson Wannasai, Nirush Lertprasertsuke
Scientific Reports.2023;[Epub] CrossRef
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis
Wenjie Liu, Gengwei Huo, Peng Chen
Immunotherapy.2023; 15(10): 751. CrossRef
Immunology and immunotherapy in gastric cancer
Xiaqing Xu, Jiaxing Chen, Wenxing Li, Chenlu Feng, Qian Liu, Wenfang Gao, Meng He
Clinical and Experimental Medicine.2023; 23(7): 3189. CrossRef
Targeted Therapies and Developing Precision Medicine in Gastric Cancer
Rille Pihlak, Caroline Fong, Naureen Starling
Cancers.2023; 15(12): 3248. CrossRef
Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
T. N. Sotnikova, N. V. Danilova, P. G. Malkov, T. V. Polushkina
Advances in Molecular Oncology.2023; 10(2): 70. CrossRef
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives
Yasushi Sato, Koichi Okamoto, Yutaka Kawano, Akinari Kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama
Journal of Clinical Medicine.2023; 12(14): 4646. CrossRef
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Drolaiz H. W. Liu, Heike I. Grabsch, Beat Gloor, Rupert Langer, Bastian Dislich
Journal of Cancer Research and Clinical Oncology.2023; 149(14): 13345. CrossRef
Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
Zhen Zhang, Jiaqian Huang, Yuhong Xu, Huiyan Luo
MedComm – Future Medicine.2023;[Epub] CrossRef
Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?
Hassan Abushukair, Obada Ababneh, Ayah Al-Bzour, Ibrahim Halil Sahin, Anwaar Saeed
Expert Review of Molecular Diagnostics.2023; 23(10): 863. CrossRef
Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer
Minkyue Shin, Soomin Ahn, Jaeyun Jung, Sujin Hyung, Kyoung‐Mee Kim, Seung Tae Kim, Won Ki Kang, Jeeyun Lee
Cancer Medicine.2023; 12(18): 18633. CrossRef
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy
Ion Negura, Mariana Pavel-Tanasa, Mihai Danciu
Cancer Treatment Reviews.2023; 120: 102629. CrossRef
The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer
Ji Eun Choi, Jae Seok Lee, Min-Sun Jin, Ilias P. Nikas, Kwangsoo Kim, Sunah Yang, Soo Young Park, Jiwon Koh, Sohyeon Yang, Seock-Ah Im, Han Suk Ryu
Breast Cancer Research.2023;[Epub] CrossRef
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial
Shirish Gadgeel, Fred R. Hirsch, Keith Kerr, Fabrice Barlesi, Keunchil Park, Achim Rittmeyer, Wei Zou, Namrata Bhatia, Hartmut Koeppen, Sarah M. Paul, David Shames, Jing Yi, Christina Matheny, Marcus Ballinger, Mark McCleland, David R. Gandara
Clinical Lung Cancer.2022; 23(1): 21. CrossRef
Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy
Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee
Radiology.2022; 302(1): 129. CrossRef
Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies
Matthew W. Rosenbaum, Raul S. Gonzalez
Seminars in Diagnostic Pathology.2022; 39(1): 48. CrossRef
Histopathology of Gastrointestinal Immune-related Adverse Events
M. Lisa Zhang, Vikram Deshpande
American Journal of Surgical Pathology.2022; 46(1): e15. CrossRef
Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
D.V.T. Catenacci, H.C. Chung, L. Shen, M. Moehler, H.H. Yoon, M.K. Rosales, Y.-K. Kang
ESMO Open.2022; 7(1): 100360. CrossRef
PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance
Jie Lian, Guanjun Zhang, Yun Zhang, Heng Liu, Jiaojiao Zhang, Pengfei Nan, Wei Tian
Digestive and Liver Disease.2022; 54(10): 1419. CrossRef
Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer
Enoch Kang, Sung Cheol Jung, Soo Kyung Nam, Yujun Park, Soo Hyun Seo, Kyoung Un Park, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee
Scientific Reports.2022;[Epub] CrossRef
Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim
Biomedicines.2022; 10(3): 543. CrossRef
Immunotherapy use in oesophagogastric cancers—a review of the literature
Annabel Smith, Amitesh Roy, Christos S. Karapetis, Vy Broadbridge, Timothy Price
British Journal of Cancer.2022; 127(1): 21. CrossRef
Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers
Bastian Dislich, Kirsten D. Mertz, Beat Gloor, Rupert Langer
Cancers.2022; 14(7): 1736. CrossRef
Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
Mary E. Booth, Elizabeth C. Smyth
BioDrugs.2022; 36(4): 473. CrossRef
Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
Man Jiang, Chuantao Zhang, Yabin Hu, Tianjun Li, Guangjie Yang, Guanqun Wang, Jingjuan Zhu, Changfeng Shao, Helei Hou, Na Zhou, Kewei Liu, Xiaochun Zhang
The Oncologist.2022; 27(11): e856. CrossRef
Abdominal Computed Tomography Enhanced Image Features under an Automatic Segmentation Algorithm in Identification of Gastric Cancer and Gastric Lymphoma
Lihua Zhou, Hao Hu, Lei Zhou, Yi Zhou, Ahmed Faeq Hussein
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
D.V.T. Catenacci, Y.-K. Kang, H.H. Yoon, B.Y. Shim, S.T. Kim, D.-Y. Oh, A.I. Spira, S.V. Ulahannan, E.J. Avery, P.M. Boland, J. Chao, H.C. Chung, F. Gardner, S.J. Klempner, K.-W. Lee, S.C. Oh, J. Peguero, M.B. Sonbol, L. Shen, M. Moehler, J. Sun, D. Li, M
ESMO Open.2022; 7(5): 100563. CrossRef
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
Hongzhen Cai, Man Li, Ruiyi Deng, Mopei Wang, Yanyan Shi
Biomarker Research.2022;[Epub] CrossRef
Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
Kathryn DeCarli, Jonathan Strosberg, Khaldoun Almhanna
Cancers.2022; 14(17): 4201. CrossRef
Immunotherapy for Gastroesophageal Tumors: Is there still Hope for Efficacy?
Hannah Christina Puhr, Aysegul Ilhan-Mutlu
Current Cancer Drug Targets.2022; 22(8): 651. CrossRef
The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers
Corina-Elena Minciuna, Mihai Tanase, Teodora Ecaterina Manuc, Stefan Tudor, Vlad Herlea, Mihnea P. Dragomir, George A. Calin, Catalin Vasilescu
Computational and Structural Biotechnology Journal.2022; 20: 5065. CrossRef
Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer
Zhen Jiang, Chen Wei, Yaomin Luo, Yang Xiao, Li Wang, Wubin Guo, Xiaoxia Yuan
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate
Ji Min Kim, Binnari Kim, Eunji Kim, Minsun Jang, Jun Hun Cho, Hye Seung Lee, Yoonjin Kwak, Lingkang Huang, Radha Krishnan, Sally Y. Bai, Mounia Mounawar, Kyoung-Mee Kim
Molecular Diagnosis & Therapy.2022; 26(6): 679. CrossRef
High interobserver and intraobserver reproducibility among pathologists assessing PD‐L1 CPS across multiple indications
Shanthy Nuti, Yiwei Zhang, Nabila Zerrouki, Charlotte Roach, Gudrun Bänfer, George L Kumar, Edward Manna, Rolf Diezko, Kristopher Kersch, Josef Rüschoff, Bharat Jasani
Histopathology.2022; 81(6): 732. CrossRef
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Lianxi Song, Liang Zeng, Huan Yan, Qinqin Xu, Qing Xia, Jian Lei, Xiaoyan Chen, Xiaoping Hu, Zhan Wang, Hong Liu, Nong Yang, Yongchang Zhang
Communications Medicine.2022;[Epub] CrossRef
Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer
Jan Hrudka, Radoslav Matěj, Andrej Nikov, Igor Tomyak, Hana Fišerová, Karolína Jelínková, Petr Waldauf
Scientific Reports.2022;[Epub] CrossRef
Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma
Satoshi Yamashita, Hiroyuki Abe, Akiko Kunita, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku
Histopathology.2021; 78(3): 381. CrossRef
MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma
Daniel V T Catenacci, Minori Rosales, Hyun Cheol Chung, Harry H Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang
Future Oncology.2021; 17(10): 1155. CrossRef
PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study
You Jeong Heo, Binnari Kim, Hyunjin Kim, Soi Kim, Min Sun Jang, Kyoung-Mee Kim
Pathology - Research and Practice.2021; 218: 153338. CrossRef
Targeting Oncoimmune Drivers of Cancer Metastasis
Chie Kudo-Saito, Yukinori Ozaki, Hiroshi Imazeki, Hideyuki Hayashi, Jun Masuda, Hiroki Ozawa, Yamato Ogiwara
Cancers.2021; 13(3): 554. CrossRef
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming Sound Tsao, Fred R. Hirsch
Nature Reviews Clinical Oncology.2021; 18(6): 345. CrossRef
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey, Baolin Zhang
The AAPS Journal.2021;[Epub] CrossRef
High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong
Diagnostics.2021; 11(4): 597. CrossRef
Prädiktive Diagnostik für Checkpoint-Inhibitoren
Hans-Ulrich Schildhaus, Wilko Weichert
Der Pathologe.2021; 42(4): 380. CrossRef
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Enrico Munari, Francesca R. Mariotti, Linda Quatrini, Pietro Bertoglio, Nicola Tumino, Paola Vacca, Albino Eccher, Francesco Ciompi, Matteo Brunelli, Guido Martignoni, Giuseppe Bogina, Lorenzo Moretta
International Journal of Molecular Sciences.2021; 22(10): 5123. CrossRef
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
Soomin Ahn, Kyoung-Mee Kim
Modern Pathology.2021; 34(9): 1719. CrossRef
PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
Tamara Z. Dabbagh, Maher A. Sughayer
Applied Immunohistochemistry & Molecular Morphology.2021; 29(6): 462. CrossRef
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry
Yujun Park, An Na Seo, Jiwon Koh, Soo Kyoung Nam, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
OncoImmunology.2021;[Epub] CrossRef
Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Tong Xie, Zhening Zhang, Xiaotian Zhang, Changsong Qi, Lin Shen, Zhi Peng
Frontiers in Oncology.2021;[Epub] CrossRef
Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
Hye Jung Hwang, Soo Kyung Nam, Hyunjin Park, Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Woo Ho Kim, Hye Seung Lee
Journal of Pathology and Translational Medicine.2020; 54(5): 378. CrossRef

17,932 View
717 Download
76 Web of Science
79 Crossref

Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers: Jeong Mo Bae, Xianyu Wen, Tae-Shin Kim, Yoonjin Kwak, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang; Cancer Res Treat. 2020;52(1):74-84. Published online May 8, 2019; DOI: https://doi.org/10.4143/crt.2019.062

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to reveal the clinicopathological characteristics and prognostic implications associated with fibroblast growth factor receptor 1 (FGFR1) amplification in colorectal cancers (CRCs).
Materials and Methods
We measured the copy number of FGFR1 by droplet digital polymerase chain reaction (ddPCR), and analyzed the FGFR1 expression by immunohistochemistry, in 764 surgically resected CRCs (SNUH2007 dataset, 384 CRCs; SNUH Folfox dataset, 380 CRCs).
Results
CRCs with ≥ 3.3 copies of the FGFR1 gene were classified as FGFR1 amplified. FGFR1 amplification was found in 10 of the 384 CRCs (2.6%) in the SNUH2007 dataset, and in 28 of the 380 CRCs (7.4%) in the SNUH Folfox dataset. In the SNUH2007 dataset, there was no association between the FGFR1 copy number status and sex, gross appearance, stage, or differentiation. High FGFR1 expression was associated with female sex and KRAS mutation. At the molecular level, FGFR1 amplification was mutually exclusive with BRAF mutation, microsatellite instability, and MLH1 methylation, in both SNUH2007 and SNUH Folfox datasets. Survival analysis revealed that FGFR1 amplification was associated with significantly worse clinical outcome compared with no FGFR1 amplification, in both SNUH2007 and SNUH Folfox datasets. Within the SNUH2007 dataset, CRC patients with high FGFR1 expression had an inferior progression-free survival compared with those with low FGFR1 expression. The FGFR inhibitor, PD173074, repressed the proliferation of a CRC cell line overexpressing FGFR1, but not of cells with FGFR1 amplification.
Conclusion
FGFR1 amplification measured by ddPCR can be a prognostic indicator of poor clinical outcome in patients with CRCs.

Citations

Citations to this article as recorded by

A panorama of colon cancer in the era of liquid biopsy
Sylvie Devalle, Veronica Aran, Cesar de Souza Bastos Júnior, Vera Lucia Pannain, Paulo Brackmann, Marcelo Leal Gregório, José Eduardo Ferreira Manso, Vivaldo Moura Neto
The Journal of Liquid Biopsy.2024; 4: 100148. CrossRef
Targeting FGFR1 by β,β-dimethylacrylalkannin suppresses the proliferation of colorectal cancer in cellular and xenograft models
Ran Zhao, Fanxiang Yin, Mangaladoss Fredimoses, Jianhua Zhao, Xiaorong Fu, Beibei Xu, Mengrui Liang, Hanyong Chen, Kangdong Liu, Mingjuan Lei, Kyle Vaughn Laster, Zhi Li, Joydeb Kumar Kundu, Zigang Dong, Mee-Hyun Lee
Phytomedicine.2024; 129: 155612. CrossRef
Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies
César Gutiérrez Pérez, Enrique Lastra Aras, Patricia Saiz López, Enrique García Toro, Carmen Blanco Abad, Inmaculada Rodríguez Ledesma, María Pumares González, Miriam Vela Domínguez, Noelia Espinosa Cabria, Guillermo Crespo Herrero
Clinical and Translational Oncology.2024;[Epub] CrossRef
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research.2024;[Epub] CrossRef
Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer
Gilhyang Kim, Song Kook Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim
Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Detection and Quantification of Stagonosporopsis cucurbitacearum in Seeds of Cucurbita maxima Using Droplet Digital Polymerase Chain Reaction
Sergio Murolo, Marwa Moumni, Valeria Mancini, Mohamed Bechir Allagui, Lucia Landi, Gianfranco Romanazzi
Frontiers in Microbiology.2022;[Epub] CrossRef
Fibroblast growth factor 2: Role in prenatal alcohol-induced stimulation of hypothalamic peptide neurons
Guo-Qing Chang, Nushrat Yasmin, Adam D. Collier, Olga Karatayev, Nailya Khalizova, Amanda Onoichenco, Milisia Fam, Avi S. Albeg, Samantha Campbell, Sarah F. Leibowitz
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2022; 116: 110536. CrossRef
Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer
Elaine S. Tan, Todd C. Knepper, Xuefeng Wang, Jennifer B. Permuth, Liang Wang, Jason B. Fleming, Hao Xie
Cancers.2022; 14(9): 2223. CrossRef
Tumor-induced Osteomalacia: A Systematic Review and Individual Patient’s Data Analysis
Domenico Rendina, Veronica Abate, Giuseppe Cacace, Lanfranco D’Elia, Gianpaolo De Filippo, Silvana Del Vecchio, Ferruccio Galletti, Alberto Cuocolo, Pasquale Strazzullo
The Journal of Clinical Endocrinology & Metabolism.2022; 107(8): e3428. CrossRef
Indications of Genomic Abnormalities for Molecular Targeted Therapy in Colorectal Cancer
Koshi Mimori
Nippon Daicho Komonbyo Gakkai Zasshi.2022; 75(10): 449. CrossRef
Onco-ontogeny recapitulates phylogeny – a consideration
P. N. Plowman, C. E. Plowman
Oncogene.2021; 40(8): 1542. CrossRef
Integrating Multi–Omics Data for Gene-Environment Interactions
Yinhao Du, Kun Fan, Xi Lu, Cen Wu
BioTech.2021; 10(1): 3. CrossRef
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, Yang Wang, Yuquan Wei, Xiawei Wei
Cell Proliferation.2021;[Epub] CrossRef
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Harriet R. Ferguson, Michael P. Smith, Chiara Francavilla
Cells.2021; 10(5): 1201. CrossRef
Identification of Prognostic Dosage-Sensitive Genes in Colorectal Cancer Based on Multi-Omics
Zhiqiang Chang, Xiuxiu Miao, Wenyuan Zhao
Frontiers in Genetics.2020;[Epub] CrossRef
Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients

Jianxia Li, Jianwei Zhang, Huabin Hu, Yue Cai, Jiayu Ling, Zehua Wu, Yanhong Deng
Cancer Management and Research.2020; Volume 12: 3301. CrossRef
Identification of Genomic Alterations of Perineural Invasion in Patients with Stage II Colorectal Cancer

Hao Su, Chen Chang, Jiajie Hao, Xin Xu, Mandula Bao, Shou Luo, Chuanduo Zhao, Qian Liu, Xishan Wang, Zhixiang Zhou, Haitao Zhou
OncoTargets and Therapy.2020; Volume 13: 11571. CrossRef
Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors
Yan Zhang, Niefang Yu
Letters in Drug Design & Discovery.2020; 17(11): 1330. CrossRef

8,590 View
299 Download
18 Web of Science
18 Crossref

Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer: Sumi Yun, Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee; Cancer Res Treat. 2018;50(4):1351-1361. Published online January 17, 2018; DOI: https://doi.org/10.4143/crt.2017.487

Abstract PDF Supplementary Material PubReader ePub

Purpose
Molecular treatments targeting epidermal growth factor receptors (EGFRs) are important strategies for advanced colorectal cancer (CRC). However, clinicopathologic implications of EGFRs and EGFR ligand signaling have not been fully evaluated. We evaluated the expression of EGFR ligands and correlation with their receptors, clinicopathologic factors, and patients’ survival with CRC.
Materials and Methods
The expression of EGFR ligands, including heparin binding epidermal growth factor-like growth factor (HBEGF), transforming growth factor (TGF), betacellulin, and epidermal growth factor (EGF), were evaluated in 331 consecutive CRC samples using mRNA in situ hybridization (ISH). We also evaluated the expression status of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and HER4 using immunohistochemistry and/or silver ISH.
Results
Unlike low incidences of TGF (38.1%), betacellulin (7.9%), and EGF (2.1%), HBEGF expression was noted in 62.2% of CRC samples. However, the expression of each EGFR ligand did not reveal significant correlations with survival. The combined analyses of EGFR ligands and EGFR expression indicated that the ligands‒/EGFR+ group showed a significant association with the worst disease-free survival (DFS; p=0.018) and overall survival (OS; p=0.005). It was also an independent, unfavorable prognostic factor for DFS (p=0.026) and OS (p=0.007). Additionally, HER4 nuclear expression, regardless of ligand expression, was an independent, favorable prognostic factor for DFS (p=0.034) and OS (p=0.049), by multivariate analysis.
Conclusion
Ligand-independent EGFR overexpression was suggested to have a significant prognostic impact; thus, the expression status of EGFR ligands, in addition to EGFR, might be necessary for predicting patients' outcome in CRC.

Citations

Citations to this article as recorded by

Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer
Harshabad Singh, Ashley Kang, Lisa Bloudek, Ling-I Hsu, Maria Corinna Palanca-Wessels, Michael Stecher, Muriel Siadak, Kimmie Ng
JNCI Cancer Spectrum.2024;[Epub] CrossRef
Molecular characterization of colorectal mucinous adenocarcinoma and adenocarcinoma, not otherwise specified, identified by multiomic data analysis
Kailun Xu, Shu Zheng, Baosheng Li, Yingkuan Shao, Xiaoyang Yin
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
Mechanism of 5-fluorouracil nanoparticles on releasing skin squamous cell carcinoma through regulation of Wnt/β-catenin expression
Lixin Peng, Xinping Zhang, Bin Du, Liangliang Sun, Yuguang Zhao
Materials Express.2022; 12(2): 220. CrossRef
Research on Anti-Tumor Nano-Particle with New Type 5-Fluorouracil on the Peritoneal Metastasis of Breast Cancer
Yujie Xiao, Guilin Huang, Yibo Xiang
Journal of Biomaterials and Tissue Engineering.2021; 11(7): 1277. CrossRef
Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Constantin Stefani, Daniela Miricescu, Iulia-Ioana Stanescu-Spinu, Remus Iulian Nica, Maria Greabu, Alexandra Ripszky Totan, Mariana Jinga
International Journal of Molecular Sciences.2021; 22(19): 10260. CrossRef
SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF
Weikai Xiao, Shaoquan Zheng, Xinhua Xie, Xing Li, Lijuan Zhang, Anli Yang, Jian Wang, Hailin Tang, Xiaoming Xie
Molecular Therapy - Oncolytics.2020; 17: 118. CrossRef
Combined Therapeutic Effects of ¹³¹I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer

Pingping Wu, Huayun Zhu, Yan Zhuang, Xiaofeng Sun, Ning Gu
International Journal of Nanomedicine.2020; Volume 15: 2777. CrossRef
Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon
Pingping Wu, Qing Zhou, Huayun Zhu, Yan Zhuang, Jun Bao
BMC Cancer.2020;[Epub] CrossRef
HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition
Xiaojing Jia, Huien Wang, Zhongxin Li, Jing Yan, Yan Guo, Wujie Zhao, Lixia Gao, Bin Wang, Yitao Jia
Molecular Medicine Reports.2020;[Epub] CrossRef
Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery
A. A. Rosenkranz, T. A. Slastnikova
Biochemistry (Moscow).2020; 85(9): 967. CrossRef
Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan M. Seddon, Helmout Modjtahedi
Oncotarget.2019; 10(18): 1704. CrossRef

9,629 View
219 Download
12 Web of Science
11 Crossref

Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors: Myong Hoon Ihn, Duck-Woo Kim, Sukki Cho, Heung-Kwon Oh, Sanghoon Jheon, Kwhanmien Kim, Eun Shin, Hye Seung Lee, Jin-Haeng Chung, Sung-Bum Kang; Cancer Res Treat. 2017;49(1):104-115. Published online May 9, 2016; DOI: https://doi.org/10.4143/crt.2015.367

Abstract PDF PubReader ePub

Purpose
Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from CRC.
Materials and Methods
Between June 2003 and December 2011, 122 patients with CRC underwent curative resection of PM detected at least 4 months after CRC resection. Clinico-pathological factors selected from the prospectively maintained database were analyzed retrospectively.
Results
The median disease-free interval (DFI) between resection of the primary tumor and detection of PM was 22.0 months (range, 4 to 85 months). Solitary PM were detected in 77 patients (63.1%), with a median maximal tumor diameter of 12.0 mm (range, 2 to 70 mm). Of 52 patients who underwent mediastinal lymph node (LN) dissection, eight patients had LN involvement. Five-year overall survival and disease-free survival (DFS) rates after initial pulmonary metastasectomy were 66.4% and 50.9%, respectively. DFI, mediastinal LN involvement, and the number and distribution of PM were significantly prognostic factors for DFS. In multivariable analysis DFI ≥ 12 months, solitary lesion, and absence of mediastinal LN involvement were independently prognostic for DFS. Of the 122 patients, 48 patients (39.3%) developed recurrent PM a median 13.0 months after initial pulmonary metastasectomy. Recurrent DFI was independently prognostic of DFS in patients who underwent repeated pulmonary metastasectomy.
Conclusion
There is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent PM. Pulmonary metastasectomy should be considered in selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.

Citations

Citations to this article as recorded by

circEIF3I Promotes Colorectal Cancer Metastasis by Regulating the miR‐328‐3p/NCAPH Axis
Yali Zhao, Yan He, Zhiyuan Xiao, Le Xin, Mingjing Deng, Mingxia Yao, Guan Huang
Molecular Carcinogenesis.2025; 64(3): 450. CrossRef
Outcomes and prognostic factors of repeat pulmonary metastasectomy
Ryu Kanzaki, Hirokazu Watari, Akiisa Omura, Sachi Kawagishi, Ryo Tanaka, Tomohiro Maniwa, Jiro Okami
Interdisciplinary CardioVascular and Thoracic Surgery.2024;[Epub] CrossRef
Development of a protocol for whole-lung in vivo lung perfusion-assisted photodynamic therapy using a porcine model
Khaled Ramadan, Tina Saeidi, Edson Brambate, Vanderlei Bagnato, Marcelo Cypel, Lothar Lilge
Journal of Biomedical Optics.2024;[Epub] CrossRef
Role of Pulmonary Metastasectomy in Colorectal Cancer
Zamaan Hooda, Michael Eisenberg, Mara B. Antonoff
Thoracic Surgery Clinics.2024;[Epub] CrossRef
Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer: a systematic review and meta-analysis
Andreas Gkikas, Christos Kakos, Savvas Lampridis, Peter J Godolphin, Davide Patrini
European Journal of Cardio-Thoracic Surgery.2023;[Epub] CrossRef
FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation
Lingnan He, Zijun Guo, Weijun Wang, Shuxin Tian, Rong Lin
Cell Communication and Signaling.2023;[Epub] CrossRef
PET/MRI in colorectal and anal cancers: an update
Vetri Sudar Jayaprakasam, Semra Ince, Garima Suman, Pankaj Nepal, Thomas A. Hope, Raj Mohan Paspulati, Tyler J. Fraum
Abdominal Radiology.2023; 48(12): 3558. CrossRef
A review of surgery for lung metastasis from colorectal cancer
Yu-Kwang Lee, Mong-Wei Lin, Ke-Cheng Chen, Pei-Ming Huang, Shuenn-Wen Kuo, Jang-Ming Lee
Formosan Journal of Surgery.2023;[Epub] CrossRef
Long-term outcomes and early recurrence after resection for metachronous pulmonary metastases from colorectal cancer
Shintaro Hashimoto, Tetsuro Tominaga, Takashi Nonaka, Keisuke Noda, Soishiro Kiya, Toshio Shiraishi, Kaido Oishi, Yuma Takamura, Shoto Yamazaki, Masato Araki, Yorihisa Sumida, Takuro Miyazaki, Ryotaro Kamohara, Shigeyuki Morino, Keitaro Matsumoto, Akihiro
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience
Ameera S. Balhareth, Abdullah S. AlQattan, Hassan M. Alshaqaq, Abdullah M. Alkhalifa, Alaa A. Al Abdrabalnabi, Muna S. Alnamlah, Deborah MacNamara
Annals of Medicine and Surgery.2022; 77: 103559. CrossRef
Long term survival after multiple microwave ablations for colorectal cancer lung metastases: A case report
Victoria T. Y Lee, Yueh-Hsin Lin, Derek Glenn, Suhrid Lodh, David L. Morris
Radiology Case Reports.2022; 17(6): 2038. CrossRef
A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion
Khaled Ramadan, Bruno Gomes, Mauricio Pipkin, Mariola Olkowicz, Barbara Bojko, Arnaud Romeo Mbadjeu Hondjeu, Shaf Keshavjee, Thomas Waddell, Janusz Pawliszyn, Marcelo Cypel
The Journal of Thoracic and Cardiovascular Surgery.2021; 161(5): 1626. CrossRef
Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis
Junfeng Huang, Qing Zang, Yaokai Wen, Zhe Pan, Zhiyuan Yao, Mingkai Huang, Jiongqiang Huang, Jingsong Chen, Rongchang Wang
Critical Reviews in Oncology/Hematology.2021; 160: 103308. CrossRef
Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases
Edward Alabraba, Dhanny Gomez
American Journal of Clinical Oncology.2021; 44(5): 210. CrossRef
Determination of Optical Properties and Photodynamic Threshold of Lung Tissue for Treatment Planning of In Vivo Lung Perfusion Assisted Photodynamic Therapy
Khaled T. Ramadan, Christopher McFadden, Bruno Gomes, Fynn Schwiegelshohn, Rafaela V.P. Ribeiro, Harley H.L. Chan, Vaughn Betz, Marcelo Cypel, Lothar Lilge
Photodiagnosis and Photodynamic Therapy.2021; 35: 102353. CrossRef
Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers
Oya Yıldız, Shute Ailia Dae, Alper Fındıkcıoglu, Fatih Kose
Revista da Associação Médica Brasileira.2021; 67(7): 1015. CrossRef
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer
Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu, Lu Liu
Journal of Hematology & Oncology.2021;[Epub] CrossRef
Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Journal of Cellular Biochemistry.2019; 120(6): 8815. CrossRef
Surgical management of colorectal lung metastases
Joseph D. Phillips, Rian M. Hasson
Journal of Surgical Oncology.2019; 119(5): 629. CrossRef
Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice
S. Karim, S. Nanji, K. Brennan, C.S. Pramesh, C.M. Booth
European Journal of Surgical Oncology (EJSO).2017; 43(8): 1481. CrossRef
The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study
Hiroyuki Sakae, Hiromitsu Kanzaki, Junichiro Nasu, Yutaka Akimoto, Kazuhiro Matsueda, Masao Yoshioka, Masahiro Nakagawa, Shinichiro Hori, Masafumi Inoue, Tomoki Inaba, Atsushi Imagawa, Masahiro Takatani, Ryuta Takenaka, Seiyu Suzuki, Toshiyoshi Fujiwara,
British Journal of Cancer.2017; 117(11): 1607. CrossRef

10,658 View
198 Download
24 Web of Science
21 Crossref

Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells: Mi Hyun Kang, Sung Ung Moon, Ji Hea Sung, Jin Won Kim, Keun Wook Lee, Hye Seung Lee, Jong Seok Lee, Jee Hyun Kim; Cancer Res Treat. 2016;48(1):355-364. Published online March 5, 2015; DOI: https://doi.org/10.4143/crt.2014.260

Abstract PDF PubReader ePub

Purpose
HM781-36B is a novel and irreversible pan-human epidermal growth factor receptor (HER) inhibitor with TEC cytoplasmic kinase inhibition. The aim of this study is to evaluate the antitumor activity and mechanism of action for HM781-36B in CRC cell lines.
Materials and Methods
The CRC cell lines were exposed to HM781-36B and/or oxaliplatin (L-OHP), 5-fluorouracil (5-FU), SN-38. The cell viability was examined by Cell Titer-Glo luminescent cell viability assay kit. Change in the cell cycle and protein expression was determined by flow cytometry and immunoblot analysis, respectively. Synergism between 2 drugs was evaluated by the combination index.
Results
The addition of HM781-36B induced potent growth inhibition in both DiFi cells with EGFR overexpression and SNU-175 cells (IC50 = 0.003 and 0.005 M, respectively). Furthermore, HM781-36B induced G1 arrest of the cell cycle and apoptosis, and reduced the levels of HER family and downstream signaling molecules, pERK and pAKT, as well as nonreceptor/cytoplasmic tyrosine kinase, BMX. The combination of HM781-36B with 5-FU, L-OHP, or SN-38 showed an additive or synergistic effect in most CRC cells.
Conclusion
These findings suggest the potential roles of HM781-36B as the treatment for EGFR-overexpressing colon cancer, singly or in combination with chemotherapeutic agents. The role of BMX expression as a marker of response to HM781-36B should be further explored.

Citations

Citations to this article as recorded by

Synthesis, cytotoxic evaluation, and in silico studies of novel benzenesulfonamide-thiazolidinone derivatives against colorectal carcinoma
Belma Zengin Kurt, Mustafa Gökçe, Halil Şenol, Dilek Öztürk Civelek, Gülnur Dandin, Isil Gazioglu
Journal of Molecular Structure.2025; 1321: 140153. CrossRef
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Meng Hu, Congying Zhong, Jiabing Wang, JinQin Chen, Tao Zhou
Frontiers in Immunology.2024;[Epub] CrossRef
Piperazine-derived ionizable lipids for enhanced mRNA delivery and cancer immunotherapy
Kai Xu, Yujia Xu, Jin Sun, Xinwei Cheng, Chenxi Lu, Wenzhong Chen, Bingfang He, Tianyue Jiang
Nano Research.2024; 17(8): 7357. CrossRef
A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma
Jing Yang, Yanfei Yang, Yuquan Wei, Xiawei Wei
Frontiers of Medicine.2023; 17(2): 275. CrossRef
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina C. Garassino, John V. Heymach, Mark A. Socinski, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, Xiuning L
Journal of Thoracic Oncology.2023; 18(8): 1031. CrossRef
Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski
Journal of Clinical Oncology.2022; 40(7): 710. CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
Cancers.2020; 12(11): 3249. CrossRef
miRDRN—miRNA disease regulatory network: a tool for exploring disease and tissue-specific microRNA regulatory networks
Hsueh-Chuan Liu, Yi-Shian Peng, Hoong-Chien Lee
PeerJ.2019; 7: e7309. CrossRef
Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc
Yufang Zuo, Dongyan Yang, Yin Yu, Mei Xiang, Haiwen Li, Jun Yang, Jingjing Li, Danxian Jiang, Hechao Zhou, Zumin Xu, Zhonghua Yu
Molecular Medicine Reports.2017;[Epub] CrossRef
FXR1 is elevated in colorectal cancer and acts as an oncogene
Xin Jin, Bo Zhai, Taishi Fang, Xiaohui Guo, Lishan Xu
Tumor Biology.2016; 37(2): 2683. CrossRef

16,212 View
196 Download
11 Web of Science
10 Crossref

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors: Hee Sung Kim, Hye Seung Lee, Kyung Han Nam, Jiwoon Choi, Woo Ho Kim; Cancer Res Treat. 2014;46(4):383-392. Published online July 17, 2014; DOI: https://doi.org/10.4143/crt.2013.102

Abstract PDF PubReader ePub

Purpose
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous disease group originating from the neuroendocrine cells. Identification of prognostic markers, related to neuroendocrine tissue-selective tumorigenesis, is necessary to find therapeutic targets.
Materials and Methods
A total of 327 patients with GEP-NETs were included in this study; there were 49 gastric, 29 duodenal, 49 pancreatic, 12 hepatobiliary, 33 appendiceal, 5 proximal colon, and 150 distal colon cases. We performed immunostaining with the tissue microarray method for menin, p27, and p18.
Results
We observed negative staining for menin, p27, and p18 in 34%, 21%, and 56% of GEP-NETs, respectively. The loss of p27, but not menin, was positively correlated with the grade of Ki-67. Menin–/p27–, menin–/p27+, menin+/p27–, and menin+/p27+ phenotype groups included 13%, 22%, 8%, and 57% of patients, respectively. A dichotomized comparison showed that menin– or p27– tumors were significantly associated with foregut and midgut localizations, high World Health Organization (WHO) grade, lymph node metastasis, and more advanced stage as compared to menin+/p27+ patients. Kaplan-Meier analysis for the overall survival showed that p27 loss was significantly associated with decreased survival. Multivariate analysis showed that p27 loss is an independent factor for poor overall survival.
Conclusion
Our results revealed that the loss of p27 is associated with poor prognosis and the menin-p27 pathway is important in the tumorigenesis of GEP-NETs.

Citations

Citations to this article as recorded by

Menin in Cancer
Ariana D. Majer, Xianxin Hua, Bryson W. Katona
Genes.2024; 15(9): 1231. CrossRef
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors
Brittany C. Fields, Reed I. Ayabe, Y. David Seo, Jessica E. Maxwell, Daniel M. Halperin
Current Oncology Reports.2024; 26(11): 1530. CrossRef
Status of Surveillance and Nonsurgical Therapy for Small Nonfunctioning Pancreatic Neuroendocrine Tumors
Dirk-Jan van Beek, Anna Vera D. Verschuur, Lodewijk A.A. Brosens, Gerlof D. Valk, Carolina R.C. Pieterman, Menno R. Vriens
Surgical Oncology Clinics of North America.2023; 32(2): 343. CrossRef
The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms
Liping He, Steeve Boulant, Megan Stanifer, Cuncai Guo, Anna Nießen, Mingyi Chen, Klaus Felix, Frank Bergmann, Oliver Strobel, Simon Schimmack
Cancer Science.2022; 113(5): 1575. CrossRef
Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Meng Dai, Christina S Mullins, Lili Lu, Guido Alsfasser, Michael Linnebacher
World Journal of Gastrointestinal Surgery.2022; 14(5): 383. CrossRef
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
Jasminka Hasic Telalovic, Serena Pillozzi, Rachele Fabbri, Alice Laffi, Daniele Lavacchi, Virginia Rossi, Lorenzo Dreoni, Francesca Spada, Nicola Fazio, Amedeo Amedei, Ernesto Iadanza, Lorenzo Antonuzzo
Diagnostics.2021; 11(5): 804. CrossRef
The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung
Mateusz Bilski, Paulina Mertowska, Sebastian Mertowski, Marcin Sawicki, Anna Hymos, Paulina Niedźwiedzka-Rystwej, Ewelina Grywalska
Cancers.2021; 14(1): 177. CrossRef
The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities
Kate Young, Naureen Starling, Anguraj Sadanandam
Seminars in Cancer Biology.2020; 61: 132. CrossRef
Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sa
Cancer Research.2020; 80(17): 3620. CrossRef
Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors
Pengchen Chen, Qingshui Wang, Jianwei Xie, Hang Fai Kwok
Seminars in Cancer Biology.2019; 58: 80. CrossRef
Reduced expression of the RNA‐binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis
Chongtae Kim, Da Eun Jeong, Sungeun Heo, Eunbyul Ji, Jun Gi Rho, Myeongwoo Jung, Sojin Ahn, Ye‐Jin Kim, Yong‐Sung Kim, Suk Woo Nam, Rohit N Kulkarni, Kyoung Bun Lee, Eun Kyung Lee, Wook Kim
The Journal of Pathology.2018; 246(2): 231. CrossRef
Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors
Yanhong Luo, Hua Zhu, Tao Tan, Jianfeng He
Frontiers in Pharmacology.2018;[Epub] CrossRef
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
E T Aristizabal Prada, C J Auernhammer
Endocrine Connections.2018; 7(1): R1. CrossRef
Deletion ofMen1andsomatostatininduces hypergastrinemia and gastric carcinoids
Sinju Sundaresan, Anthony J Kang, Michael M Hayes, Eun-Young K Choi, Juanita L Merchant
Gut.2017; 66(6): 1012. CrossRef
Cell Cycle Protein Expression in Neuroendocrine Tumors
Yan Shi, Zhi Rong Qian, Sui Zhang, Wanwan Li, Yohei Masugi, Tingting Li, Jennifer A. Chan, Juhong Yang, Annacarolina Da Silva, Mancang Gu, Li Liu, Tsuyoshi Hamada, Keisuke Kosumi, Trevor Dutton, Lauren K. Brais, Reiko Nishihara, Charles S. Fuchs, Shuji Og
Pancreas.2017; 46(10): 1347. CrossRef
DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications
Iris H. Liu, James M. Ford, Pamela L. Kunz
Cancer Treatment Reviews.2016; 44: 1. CrossRef
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases
Michelle Kang Kim, Fei Ye, Daguang Wang, Miao Cui, Stephen C. Ward, Richard R.P. Warner, Sasan Roayaie, Michail Shafir, Myron Schwartz, David Zhang, Steven Itzkowitz
Pancreas.2016; 45(4): 528. CrossRef
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson
Modern Pathology.2016; 29(6): 616. CrossRef
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
Pharmacological Research.2016; 107: 249. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors
Joakim Crona, Tobias Gustavsson, Olov Norlén, Katarina Edfeldt, Tobias Åkerström, Gunnar Westin, Per Hellman, Peyman Björklund, Peter Stålberg
Annals of Surgical Oncology.2015; 22(S3): 1428. CrossRef
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
Mark Kidd, Ignat Drozdov, Irvin Modlin
Endocrine-Related Cancer.2015; 22(4): 561. CrossRef

12,540 View
66 Download
26 Web of Science
22 Crossref

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors: Hee Sung Kim, Hye Seung Lee, Woo Ho Kim; Cancer Res Treat. 2011;43(3):181-188. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.181

Abstract PDF PubReader ePub

PURPOSE
This study was undertaken to evaluate the significance of cyclooxygenase-2 (COX2) overexpression and the expression of somatostatin receptor (SSTR) subtypes in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
MATERIALS AND METHODS
Two hundred and forty-seven cases of GEP-NET, comprising 86 foregut and 156 hindgut primary NETs, and 5 metastatic NETs in the liver, were studied retrospectively with immunohistochemistry for COX2, chromogranin A, Ki-67, SSTR1, SSTR2, and SSTR5.
RESULTS
COX2 overexpression was observed in 54%(126 of 234), and SSTR1, SSTR2, and SSTR5 positivity in 84%(196 of 233), 72%(168 of 233), and 55%(128 of 232), respectively. COX2 overexpression was found to be positively correlated with Ki-67 labeling index and inversely correlated with the expression of SSTR subtypes. In addition, the expression of SSTR subtypes was tightly correlated in any comparative pairs. A significant inverse correlation was found between COX2 and SSTR2 expression in the foregut, but not hindgut NETs. Kaplan-Meier analyses showed that COX2 overexpression (p=0.003) and high Ki-67 labeling index (p<0.001) were associated with poor overall survival (OS), whereas expression of SSTR2 (p<0.001) was associated with better OS of GEP-NET patients. Multivariate analysis revealed negative SSTR2 expression as an independent prognostic marker in GEP-NET patients (p<0.001).
CONCLUSION
Our results suggest that expression of SSTR subtypes is associated with favorable prognosis, whereas COX2 overexpression is associated with poor prognosis in GEP-NETs. Taken together, COX2 could be a possible therapeutic target in some subsets of GEP-NETs.

Citations

Citations to this article as recorded by

A Clinicopathological Analysis of Asian Patients with Adrenocortical Carcinoma: A Single-Center Experience
Wen-Hsuan Tsai, Shuen-Han Dai, Chun-Chuan Lee, Ming-Nan Chien, Yi-Hong Zeng
Current Oncology.2023; 30(4): 4117. CrossRef
Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
Aadil Adnan, Sandip Basu
Diagnostics.2023; 13(13): 2154. CrossRef
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, Jorge Barriuso, Angel Castaño, Marta Benavent, Vicente Alonso, Maria del Carmen Riesco, Teresa Alonso-Gordoa, Ana Custodio, Manuel Sanchez Canovas, Jorge Hernando, Carlos López, Adelaida La C
Neuroendocrinology.2022; 112(1): 88. CrossRef
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?
Giovanni Vitale, Alessandra Dicitore, Luigi Barrea, Emilia Sbardella, Paola Razzore, Severo Campione, Antongiulio Faggiano, Annamaria Colao, Manuela Albertelli, Barbara Altieri, Filomena Bottiglieri, Federica De Cicco, Sergio Di Molfetta, Giuseppe Fanciul
Reviews in Endocrine and Metabolic Disorders.2021; 22(3): 511. CrossRef
Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT
Anna-Karin Elf, Viktor Johanson, Ida Marin, Anders Bergström, Ola Nilsson, Johanna Svensson, Bo Wängberg, Peter Bernhardt, Erik Elias
Cancers.2021; 13(9): 2035. CrossRef
Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications
Giovanni Vitale, Silvia Carra, Francesco Ferraù, Elia Guadagno, Antongiulio Faggiano, Annamaria Colao
Critical Reviews in Oncology/Hematology.2020; 146: 102840. CrossRef
Comparative study of four different types of intraperitoneal mesh prostheses in rats
Rogério Aoki Fuziy, Ricardo Artigiani Neto, Elesiario Marques Caetano Junior, Ana Karina Soares Alves, Gaspar Jesus Lopes Filho, Marcelo Moura Linhares
Acta Cirurgica Brasileira.2019;[Epub] CrossRef
Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
Panpan Zhang, Jiangyuan Yu, Jie Li, Lin Shen, Nan Li, Hua Zhu, Shizhen Zhai, Yan Zhang, Zhi Yang, Ming Lu
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene
Valentina Indio, Annalisa Astolfi, Giuseppe Tarantino, Milena Urbini, Janice Patterson, Margherita Nannini, Maristella Saponara, Lidia Gatto, Donatella Santini, Italo Do Valle, Gastone Castellani, Daniel Remondini, Michelangelo Fiorentino, Margaret Von Me
International Journal of Molecular Sciences.2018; 19(3): 732. CrossRef
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature
Giovanni Vitale, Alessandra Dicitore, Concetta Sciammarella, Sergio Di Molfetta, Manila Rubino, Antongiulio Faggiano, Annamaria Colao
Endocrine-Related Cancer.2018; 25(6): R351. CrossRef
Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression
Yao-Yao Lu, Jin-Hang Gao, Chong Zhao, Shi-Lei Wen, Cheng-Wei Tang, Yu-Fang Wang
Scientific Reports.2018;[Epub] CrossRef
177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours
Emre Demirci, Levent Kabasakal, Turkay Toklu, Meltem Ocak, Onur E. Şahin, Nalan Alan-Selcuk, Ahmet Araman
Nuclear Medicine Communications.2018; 39(8): 789. CrossRef
Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome
Romain Appay, Emeline Tabouret, Mehdi Touat, Catherine Carpentier, Carole Colin, François Ducray, Ahmed Idbaih, Karima Mokhtari, Emmanuelle Uro-Coste, Caroline Dehais, Dominique Figarella-Branger
Acta Neuropathologica Communications.2018;[Epub] CrossRef
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours
Jorge Barriuso, Ana Custodio, Ruth Afonso, Vicente Alonso, Aurora Astudillo, Jaume Capdevila, Rocío García-Carbonero, Enrique Grande, Paula Jimenez-Fonseca, Mónica Marazuela, Cristina Rodríguez-Antona, Javier Aller
Cancer Treatment Reviews.2018; 70: 209. CrossRef
The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors
Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, Maria Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maecke, Jan Müller-Brand, Matthias Briel, Anja Schmitt, Aurel Perre
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(3): 468. CrossRef
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors
G. Lamberti, C. Ceccarelli, N. Brighi, I. Maggio, D. Santini, C. Mosconi, C. Ricci, G. Biasco, D. Campana
Gastroenterology Research and Practice.2017; 2017: 1. CrossRef
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review
Michael Michael, Rocio Garcia-Carbonero, Matthias M. Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J. Hicks
The Oncologist.2017; 22(3): 272. CrossRef
Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors
Ki Byung Song, Song Cheol Kim, Ji Hun Kim, Dong-Wan Seo, Seung-Mo Hong, Kwang-Min Park, Dae Wook Hwang, Jae Hoon Lee, Young-Joo Lee
Pancreas.2016; 45(2): 187. CrossRef
Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A
Nalan Neşe, Banu S. Kumbaraci, Dilek E. Baydar, Işin Kiliçaslan, Ayşegül A. Sari, Sait Şen, Ipek I. Gönül, Duygu Kankaya, Yasemin Özlük, Murat Ermete, Ayşim Özağari, Nebil Bal, Saba Kiremitçi, Kürşat Yildiz, Burçin Tuna, Nilay Şen, Kutsal Yörükoğlu
Applied Immunohistochemistry & Molecular Morphology.2016; 24(4): 253. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers
Kai Duan, Ozgur Mete
Cancer Cytopathology.2016; 124(12): 871. CrossRef
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors
Zhi Rong Qian, Tingting Li, Monica Ter-Minassian, Juhong Yang, Jennifer A. Chan, Lauren K. Brais, Yohei Masugi, Arunthathi Thiaglingam, Nichole Brooks, Reiko Nishihara, Mireille Bonnemarie, Atsuhiro Masuda, Kentaro Inamura, Sun A. Kim, Kosuke Mima, Yasuta
Pancreas.2016; 45(10): 1386. CrossRef
GROWTH FACTORS AND COX2 IN WOUND HEALING: AN EXPERIMENTAL STUDY WITH EHRLICH TUMORS
Flávio L. L. SALGADO, Ricardo ARTIGIANI-NETO, Gaspar de Jesus LOPES-FILHO
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2016; 29(4): 223. CrossRef
Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Roxanne C.S. van Adrichem, Kimberly Kamp, Carolien H.M. van Deurzen, Katharina Biermann, Richard A. Feelders, Gaston J.H. Franssen, Dik J. Kwekkeboom, Leo J. Hofland, Wouter W. de Herder
Neuroendocrinology.2016; 103(5): 560. CrossRef
Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity
Charlotte Gardair, Mahtab Samimi, Antoine Touzé, Pierre Coursaget, Gérard Lorette, Agnès Caille, Ewa Wierzbicka, Anne Croué, Martine Avenel-Audran, François Aubin, Rémy Kerdraon, Eric Estève, Nathalie Beneton, Serge Guyétant
Neuroendocrinology.2015; 101(3): 223. CrossRef
Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin
Guisheng Zhou, Jim Sinnett-Smith, Shi-He Liu, Juehua Yu, James Wu, Robbi Sanchez, Stephen J. Pandol, Ravinder Abrol, John Nemunaitis, Enrique Rozengurt, F. Charles Brunicardi
Frontiers in Physiology.2014;[Epub] CrossRef
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
D J Pinato, T M Tan, S T K Toussi, R Ramachandran, N Martin, K Meeran, N Ngo, R Dina, R Sharma
British Journal of Cancer.2014; 110(1): 115. CrossRef
Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor
Punit Sharma, Niraj Naswa, Sudhir Suman KC, Luis Andres Alvarado, Alok Kumar Dwivedi, Yashwant Yadav, Rakesh Kumar, Ariachery C. Ammini, Chandrasekhar Bal
European Journal of Nuclear Medicine and Molecular Imaging.2014; 41(12): 2194. CrossRef
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
A. Mohamed, M.-P. Blanchard, M. Albertelli, F. Barbieri, T. Brue, P. Niccoli, J.-R. Delpero, G. Monges, S. Garcia, D. Ferone, T. Florio, A. Enjalbert, V. Moutardier, A. Schonbrunn, C. Gerard, A. Barlier, A. Saveanu
Endocrine Related Cancer.2014; 21(5): 691. CrossRef

12,820 View
90 Download
29 Crossref

Review Article

Tissue Array Methods for High-throughput Clinicopathologic Research: Hye Seung Lee, Woo Ho Kim; Cancer Res Treat. 2006;38(1):1-6. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.1

Abstract PDF PubReader ePub

Recent research in molecular biology has identified a significant number of novel markers, which may have diagnostic, prognostic and therapeutic significance. High-throughput tissue array method facilitates the validation of novel markers by enabling the simultaneous analysis of hundreds or thousands of tissue specimens. Tissue array slides can be analyzed using techniques such as immunohistochemistry and in situ hybridization. In this review, we give a brief overview of tissue array method and its application to high throughput clinicopathologic research.

Citations

Citations to this article as recorded by

Distinctive Phenotypic and Microenvironmental Characteristics of Neuroendocrine Carcinoma and Adenocarcinoma Components in Gastric Mixed Adenoneuroendocrine Carcinoma
Yoonjin Kwak, Soo Kyung Nam, Yujun Park, Yun-Suhk Suh, Sang-Hoon Ahn, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Hyung-Ho Kim, Han-Kwang Yang, Hye Seung Lee
Modern Pathology.2024; 37(10): 100568. CrossRef
Prognostic significance of CD8 and TCF1 double positive T cell subset in microsatellite unstable gastric cancer
Juhyeong Park, Soo Kyung Nam, Yoonjin Kwak, Hyeon Jeong Oh, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Han-Kwang Yang, Hye Seung Lee
Scientific Reports.2024;[Epub] CrossRef
Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy
Sumi Yun, Jiwon Koh, Soo Kyung Nam, Yoonjin Kwak, Sang-Hoon Ahn, Joong Do Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Cancer Immunology, Immunotherapy.2021; 70(2): 431. CrossRef
Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer
Yoonjin Kwak, Jiwon Koh, Yujun Park, Yun Ji Hong, Kyoung Un Park, Hyung-Ho Kim, Do Joong Park, Sang-Hoon Ahn, Woo Ho Kim, Hye Seung Lee
British Journal of Cancer.2020; 122(9): 1399. CrossRef
Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
Dae Wook Hwang, Eun Shin, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon
Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(2): 127. CrossRef
Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
Yoonjin Kwak, Sumi Yun, Soo Kyung Nam, An Na Seo, Kyu Sang Lee, Eun Shin, Heung-Kwon Oh, Duck Woo Kim, Sung Bum Kang, Woo Ho Kim, Hye Seung Lee
Journal of Translational Medicine.2017;[Epub] CrossRef
Overexpression of Neuron-Specific Enolase as a Prognostic Factor in Patients with Gastric Cancer
Taejin Park, Young-Joon Lee, Sang-Ho Jeong, Sang-Kyung Choi, Eun-Jung Jung, Young-tae Ju, Chi-Young Jeong, Miyeong Park, Young-Sool Hah, Jiyun Yoo, Woo-Song Ha, Soon-Chan Hong, Gyung Hyuck Ko
Journal of Gastric Cancer.2017; 17(3): 228. CrossRef
Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer
Yoonjin Kwak, Jiwon Koh, Duck-Woo Kim, Sung-Bum Kang, Woo Ho Kim, Hye Seung Lee
Oncotarget.2016; 7(49): 81778. CrossRef
A Possible Link Between Parathyroid Hormone Secretion and Local Regulation of GABA in Human Parathyroid Adenomas
A Ram Hong, Young A Kim, Jae Hyun Bae, Hye Sook Min, Jung Hee Kim, Chan Soo Shin, Seong Yeon Kim, Sang Wan Kim
The Journal of Clinical Endocrinology & Metabolism.2016; 101(6): 2594. CrossRef
Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation
Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Duck-Woo Kim, Sung-Bum Kang, Woo Ho Kim, Hye Seung Lee
Pathobiology.2015; 82(2): 76. CrossRef
The Clinical Implication of Cancer-Associated Microvasculature and Fibroblast in Advanced Colorectal Cancer Patients with Synchronous or Metachronous Metastases
Yoonjin Kwak, Hee Eun Lee, Woo Ho Kim, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee, Anthony W. I. Lo
PLoS ONE.2014; 9(3): e91811. CrossRef
Prognostic value of CAPZA1 overexpression in gastric cancer
YOUNG-JOON LEE, SANG-HO JEONG, SOON-CHAN HONG, BOK-IM CHO, WOO-SONG HA, SOON-TAE PARK, SANG-KYUNG CHOI, EUN-JUNG JUNG, YOUNG-TAE JU, CHI-YOUNG JEONG, JAE WON KIM, CHANG WON LEE, JIYUN YOO, GYUNG HYUCK KO
International Journal of Oncology.2013; 42(5): 1569. CrossRef
TUFM is a potential new prognostic indicator for colorectal carcinoma
Hongjun Shi, Mark Hayes, Chandra Kirana, Rosemary Miller, John Keating, Donia Macartney-Coxson, Richard Stubbs
Pathology.2012; 44(6): 506. CrossRef
Laparoscopic Assisted Distal Rectal Cancer Resection with Preoperative Concurrent Chemoradiotherapy
Bong Hwa Lee, Mi Young Chang, Sung Kook Park, Taeik Eum, Hyun Joo Shin, Nam Kyu Ro, Chang Nam An, Hae Wan Lee, Lee Su Kim, Hyoung-Chul Park, Hoon Sik Bae, Dae Young Zang, Richard L Whelan
Cancer Research and Treatment.2007; 39(1): 10. CrossRef

13,281 View
77 Download
14 Crossref

Original Articles

Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers: Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe; Cancer Res Treat. 2005;37(2):98-102. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.98

Abstract PDF PubReader ePub

Purpose

DNA-PKcs is one of the DNA repair genes. It was recently found that hyperplasia and dysplasia of the intestinal mucosa and the production of aberrant crypt foci were developed in DNA-PKcs-null mice, and this suggests a suppressive role for DNA-PKcs in tumorigenesis.

Materials and Methods

To investigate the possible relationship between the clinico-pathologic characteristics and the survival of gastric cancer patients, the expression status of DNA-PKcs was determined in 279 consecutive gastric cancers. Immunohistochemical analysis was performed to evaluate the expression levels of DNA-PKcs protein by using the tissue array method.

Results

Out of 279 consecutive gastric cancers, 63 cases (22.6%) showed the loss of DNA-PKcs expression. The loss of DNA-PKcs expression was significantly associated with advanced cancer (p<0.001), lymphatic invasion (p=0.001), lymph node metastasis (p=0.009), and advanced pTNM stage (p=0.009). Univariate survival analysis revealed that patients with the loss of DNA-PKcs expression had significantly poorer survival than those patients with intact DNA-PKcs expression (p=0.004). Moreover, the loss of DNA-PKcs expression was identified to correlate with a lower survival in the subgroup of stage I gastric cancer patients (p=0.037).

Conclusion

The loss of DNA-PKcs expression was found in 23% of human gastric cancers and this was identified to significantly correlate with poor patient survival, especially for stage I gastric cancer patients.

Citations

Citations to this article as recorded by

Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer
Yu Bin Ng, Semih Can Akincilar
Current Opinion in Pharmacology.2024; 76: 102460. CrossRef
An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma
Zhonghai Du, Xiuchen Han, Liping Zhu, Li Li, Leandro Castellano, Justin Stebbing, Ling Peng, Zhiqiang Wang
BMC Medical Genomics.2024;[Epub] CrossRef
Secrets of DNA-PKcs beyond DNA repair
Sydney Camfield, Sayan Chakraborty, Shailendra Kumar Dhar Dwivedi, Pijush Kanti Pramanik, Priyabrata Mukherjee, Resham Bhattacharya
npj Precision Oncology.2024;[Epub] CrossRef
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)
Suwen Hu, Zi Hui, Frédéric Lirussi, Carmen Garrido, Xiang-Yang Ye, Tian Xie
Expert Opinion on Therapeutic Patents.2021; 31(5): 435. CrossRef
Role of PRKDC in cancer initiation, progression, and treatment
Yu Chen, Yi Li, Jiani Xiong, Bin Lan, Xuefeng Wang, Jun Liu, Jing Lin, Zhaodong Fei, Xiaobin Zheng, Chuanben Chen
Cancer Cell International.2021;[Epub] CrossRef
Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer
Abdullah Saleh Al-wajeeh, Salizawati Muhamad Salhimi, Majed Ahmed Al-Mansoub, Imran Abdul Khalid, Thomas Michael Harvey, Aishah Latiff, Mohd Nazri Ismail, John Matthew Koomen
PLOS ONE.2020; 15(1): e0227404. CrossRef
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
Kien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, Jen-Hao Cheng, Wen-Liang Fang, Yi-Chen Yeh, Yu-Chao Wang, Dennis Shin-Shian Hsu, Chiao-En Wu, Jiun-I Lai, Peter Mu-Hsin Chang, Ming-Han Chen, Meng-Lun Lu, Shu-Jen Chen, Yee Chao, Michael Hsiao, Ming-Huang Chen
Journal for ImmunoTherapy of Cancer.2020; 8(1): e000485. CrossRef
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Michaela Medová, Matúš Medo, Lusine Hovhannisyan, Carmen Muñoz-Maldonado, Daniel M. Aebersold, Yitzhak Zimmer
Pharmacology & Therapeutics.2020; 215: 107617. CrossRef
DNA-dependent protein kinase: Epigenetic alterations and the role in genomic stability of cancer
Vazhappilly Cijo George, Shabbir Ahmed Ansari, Vipin Shankar Chelakkot, Ayshwarya Lakshmi Chelakkot, Chaithanya Chelakkot, Varsha Menon, Wafaa Ramadan, Kannatt Radhakrishnan Ethiraj, Raafat El-Awady, Theodora Mantso, Melina Mitsiogianni, Mihalis I. Panagi
Mutation Research/Reviews in Mutation Research.2019; 780: 92. CrossRef
Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer
Xiang Zhang, Yanlin Wang, Yuan Ning
Urologic Oncology: Seminars and Original Investigations.2017; 35(3): 111.e15. CrossRef
Ab initio and QSAR study of several etoposides as anticancer drugs: Solvent effect
R. Sayyadi kord Abadi, A. Alizadehdakhel, S. Dorani Shiraz
Russian Journal of Physical Chemistry B.2017; 11(2): 307. CrossRef
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock Sishc, Anthony Davis
Cancers.2017; 9(7): 81. CrossRef
PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients
Gang Sun, Le Yang, Chao Dong, Bin Ma, Meihui Shan, Binlin Ma
Oncology Reports.2017; 37(6): 3536. CrossRef
DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability
Z Shang, L Yu, Y-F Lin, S Matsunaga, C-Y Shen, B P C Chen
Oncogenesis.2014; 3(2): e85. CrossRef
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers
Tarek Abdel-Fatah, Arvind Arora, Devika Agarwal, Paul Moseley, Christina Perry, Nicola Thompson, Andrew R. Green, Emad Rakha, Stephen Chan, Graham Ball, Ian O. Ellis, Srinivasan Madhusudan
Breast Cancer Research and Treatment.2014; 146(2): 309. CrossRef
Predictive factors for the sensitivity of radiotherapy and prognosis of esophageal squamous cell carcinoma
Shaobin Wu, Xianwei Wang, Jin-Xiang Chen, Yuxiang Chen
International Journal of Radiation Biology.2014; 90(5): 407. CrossRef
DNA-PKcs and Ku70 are Predictive Markers for Poor Prognosis of Patients With Gall Bladder Malignancies
Feng Ren, Zhu-lin Yang, Xingguo Tan, Dongcai Liu, Qiong Zou, Yuan Yuan, Jinghe Li, Lufeng Liang, Guixiang Zeng, Senlin Chen
Applied Immunohistochemistry & Molecular Morphology.2014; 22(10): 741. CrossRef
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value
M Evert, M Frau, M L Tomasi, G Latte, M M Simile, M A Seddaiu, A Zimmermann, S Ladu, T Staniscia, S Brozzetti, G Solinas, F Dombrowski, F Feo, R M Pascale, D F Calvisi
British Journal of Cancer.2013; 109(10): 2654. CrossRef
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy
JIAO YANG, XIMING XU, YANRONG HAO, JIAXIN CHEN, HEMING LU, JIAN QIN, LUXING PENG, BIAO CHEN
Oncology Letters.2013; 5(4): 1199. CrossRef
Identification of genes with a correlation between copy number and expression in gastric cancer
Lei Cheng, Ping Wang, Sheng Yang, Yanqing Yang, Qing Zhang, Wen Zhang, Huasheng Xiao, Hengjun Gao, Qinghua Zhang
BMC Medical Genomics.2012;[Epub] CrossRef
Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α′ levels
Birgitte B. Olsen, Ulrike Fischer, Tine L. Rasmussen, Matthias Montenarh, Eckart Meese, Gerhard Fritz, Olaf-Georg Issinger
Molecular and Cellular Biochemistry.2011; 356(1-2): 139. CrossRef
The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
M Someya, K-i Sakata, Y Matsumoto, R P Kamdar, M Kai, M Toyota, M Hareyama
British Journal of Cancer.2011; 104(11): 1724. CrossRef
Tissue Array Methods for High-throughput Clinicopathologic Research
Hye Seung Lee, Woo Ho Kim
Cancer Research and Treatment.2006; 38(1): 1. CrossRef

10,003 View
64 Download
23 Crossref

Prognostic Significance of CD24 Expression in Gastric Carcinoma: Nevine S. Darwish, Min A Kim, Mee Soo Chang, Hye Seung Lee, Byung Lan Lee, Yong Il Kim, Woo Ho Kim; Cancer Res Treat. 2004;36(5):298-302. Published online October 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.298

Abstract PDF PubReader ePub

Purpose

The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in hematological malignancies, as well as in a large variety of solid tumors. Its expression is now known to be related to the prognosis of several kinds of tumors. This study is designed to examine the prognostic significance of CD24 in Korean gastric cancer patients.

Materials and Methods

In the present study, we examined CD24 expression in 300 consecutive cases of gastric carcinoma by immunohistochemical staining using the tissue-array method. We also investigated the clinicopathological profiles related to CD24 expression.

Results

One hundred and three cases out of 300 (34.3%) showed the positive expression of CD24. The altered expression of CD24 was significantly associated with differentiated cancer (p=0.003), the intestinal subtype according to the Lauren classification (p<0.001), the advanced stage cancer (p=0.027), with lymphatic invasion (p=0.038) and with vascular invasion (p=0.006). The survival analysis revealed that the patients with CD24 positive expression showed significantly poorer survival than those without CD24 expression. Moreover, a combined evaluation revealed that PTEN+/CD24- cases showed the best survival compared to other groups (p=0.01).

Conclusion

Positive CD24 expression occurs in a subset of gastric carcinomas and it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival.

Citations

Citations to this article as recorded by

CD24 blockade as a novel strategy for cancer treatment
Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
International Immunopharmacology.2023; 121: 110557. CrossRef
Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200
Sun Young Moon, Minjoo Han, Gyoungah Ryu, Seong-Ah Shin, Jun Hyuck Lee, Chang Sup Lee
International Journal of Molecular Sciences.2023; 24(20): 15072. CrossRef
Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
Cancer Cell International.2021;[Epub] CrossRef
Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
Michel Vidal
Advanced Drug Delivery Reviews.2020; 161-162: 110. CrossRef
CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Yang-Hong Ni, Xia Zhao, Wei Wang
Current Gene Therapy.2020; 20(2): 109. CrossRef
DNA Aptamers for the Malignant Transformation Marker CD24
Joanna Fafińska, Andreas Czech, Tobias Sitz, Zoya Ignatova, Ulrich Hahn
Nucleic Acid Therapeutics.2018; 28(6): 326. CrossRef
The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer
S.M. Riajul Wahab, Farhadul Islam, Vinod Gopalan, Alfred King-yin Lam
Clinical Colorectal Cancer.2017; 16(2): 93. CrossRef
Clinicopathological and Prognostic Value of CD24 Expression in Breast Cancer: A Meta-Analysis
Gao Liu, Guo-Xing Liu, Yu Fang, Zhen-Yu Cao, Hui-Hui Du, Jie Fu, Ke Qian
The International Journal of Biological Markers.2017; 32(2): 182. CrossRef
CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells
Wenjie Deng, Luo Gu, Xiaojie Li, Jianchao Zheng, Yujie Zhang, Biao Duan, Jie Cui, Jing Dong, Jun Du
Journal of Translational Medicine.2016;[Epub] CrossRef
CD24 enrichment protects while its loss increases susceptibility of juvenile chondrocytes towards inflammation
Jieun Lee, Piera Smeriglio, Jason Dragoo, William J. Maloney, Nidhi Bhutani
Arthritis Research & Therapy.2016;[Epub] CrossRef
CD44v3+/CD24− cells possess cancer stem cell-like properties in human oral squamous cell carcinoma
KEITA TODOROKI, SACHIKO OGASAWARA, JUN AKIBA, MASAMICHI NAKAYAMA, YOSHIKI NAITO, NAOKO SEKI, JINGO KUSUKAWA, HIROHISA YANO
International Journal of Oncology.2016; 48(1): 99. CrossRef
CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation
Yao-An Shen, Chia-Yu Wang, Hui-Yen Chuang, John Jeng-Jong Hwang, Wei-Hsin Chi, Chih-Hung Shu, Ching-Yin Ho, Wing-Yin Li, Yann-Jang Chen
Oncotarget.2016; 7(36): 58351. CrossRef
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
Mi Jeong Kwon, Jinil Han, Ji Hyun Seo, Kyoung Song, Hae Min Jeong, Jong-Sun Choi, Yu Jin Kim, Seon-Heui Lee, Yoon-La Choi, Young Kee Shin, Yves St-Pierre
PLOS ONE.2015; 10(10): e0139112. CrossRef
Expression of CD24, p21, p53, and c‐myc in alpha‐fetoprotein‐producing gastric cancer: Correlation with clinicopathologic characteristics and survival
Xiaowen Liu, Hongmei Yu, Hong Cai, Yanong Wang
Journal of Surgical Oncology.2014; 109(8): 859. CrossRef
CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
Ying-Chao Wang, Ji-Lin Wang, Xuan Kong, Tian-Tian Sun, Hao-Yan Chen, Jie Hong, Jing-Yuan Fang
Apoptosis.2014; 19(4): 643. CrossRef
CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach
Xueyuan Cao, Donghui Cao, MeiShan Jin, Zhifang Jia, Fei Kong, Hongxi Ma, Yinping Wang, Jing Jiang
BMC Gastroenterology.2014;[Epub] CrossRef
Hypoxia‐mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion
Nobuaki Fujikuni, Hideki Yamamoto, Kazuaki Tanabe, Yutaka Naito, Naoya Sakamoto, Yuka Tanaka, Kazuyoshi Yanagihara, Naohide Oue, Wataru Yasui, Hideki Ohdan
Cancer Science.2014; 105(11): 1411. CrossRef
Clinicopathological and Prognostic Significance of CD24 Overexpression in Patients with Gastric Cancer: A Meta-Analysis
Jing-Xun Wu, Yuan-Yuan Zhao, Xuan Wu, Han-Xiang An, Yitao Ding
PLoS ONE.2014; 9(12): e114746. CrossRef
Biomarkers for predicting future metastasis of human gastrointestinal tumors
Lui Ng, Ronnie Tung Ping Poon, Roberta Pang
Cellular and Molecular Life Sciences.2013; 70(19): 3631. CrossRef
CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
Ching-Shya Yong, Chih-Ming Ou Yang, Yenn-Hwei Chou, Chao-Sheng Liao, Chung-Wei Lee, Chin-Cheng Lee
BMC Gastroenterology.2012;[Epub] CrossRef
PTEN deletion is rare but often homogeneous in gastric cancer
Sormeh Mina, Benjamin A Bohn, Ronald Simon, Antje Krohn, Matthias Reeh, Dirk Arnold, Carsten Bokemeyer, Guido Sauter, Jakob R Izbicki, Andreas Marx, Phillip R Stahl
Journal of Clinical Pathology.2012; 65(8): 693. CrossRef
Prognostic significance of loss of c-fos protein in gastric carcinoma
Seon Pil Jin, Ji Hun Kim, Min A Kim, Han-Kwang Yang, Hee Eun Lee, Hye Seung Lee, Woo Ho Kim
Pathology & Oncology Research.2007; 13(4): 284. CrossRef
Tissue Array Methods for High-throughput Clinicopathologic Research
Hye Seung Lee, Woo Ho Kim
Cancer Research and Treatment.2006; 38(1): 1. CrossRef
Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers
Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe
Cancer Research and Treatment.2005; 37(2): 98. CrossRef
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel, Glen Kristiansen
Clinical Cancer Research.2005; 11(18): 6574. CrossRef

9,705 View
61 Download
25 Crossref

Prognostic Significance of Lymph Node Micrometastasis in pT2N0 Gastric Cancer: Hyeon Kook Lee, Sam Je Cho, Yoon Ho Kim, Hye Seung Lee, Woo Ho Kim, Kuhn Uk Lee, Kuk Jin Choe, Jin Pok Kim, Han Kwang Yang; J Korean Cancer Assoc. 2001;33(2):130-135.

Abstract PDF: PURPOSE
The prognostic significance of lymph node (LN) micrometastasis in gastric cancer remains contro versial. We therefore investigated the clinicopathologic factors related to LN micrometastasis and evaluated the clinical relevance of micrometastasis with regard to urrence.
MATERIALS AND METHODS
A total of 1083 LNs from 39 patients with pT2N0 gastric cancer and who underwent curative resection in 1993 were further immunohistochemically stained using an anti-cytokeratin Ab cocktail (AE1-AE3).
RESULTS
Micrometastases were found in 3.9% (42/1083) of the resected LNs and 53.8% (21/39) of the patients with pT2N0 gastric cancer. LN micrometastasis was found to be significantly related with histologic differentiation. The recurrence rate of gastric cancer was higher in patients with LN micrometastasis (31.6%) than in those without (6.3%), with a borderline significance (p=0.074). In uni variate analysis, patients with LN micrometastasis had a shorter 5-year disease-free survival (65%) than those without LN micrometastasis (87%) (p=0.075). In multivariate analysis, multiple LN micrometastasis was associated with a poor prognosis, but with a borderline significance (p=0.069, Risk ratio 4.815) CONCLUSION: We were able to identify LN micrometastases missed on routine H-E staining, using an immuno histochemical technique. Our results suggest that LN micrometastasis is associated with the recurrence of pT2N0 gastric cancer.

3,321 View
21 Download

First
Prev
Page of 1
Next
Last

Search